The pharmaceutical manufacturing software market is growing fast. According to Research and Markets, the industry is valued at $4.43 billion in 2026 and is projected to reach $7.87 billion by 2030 — a compound annual growth rate (CAGR) of 15.5%. That growth reflects a broader shift across the life sciences industry: more organizations are replacing paper-based and legacy systems with purpose-built digital solutions.
But as software adoption accelerates, so does a critical question: is that software GxP compliant? And more importantly, has it been properly validated?
This article breaks down what GxP compliance software means, why it matters in the pharmaceutical industry, and what validation professionals need to consider when implementing it.
What is a GxP system?
GxP is an umbrella term for a collection of regulations and guidelines that govern how life sciences organizations develop, manufacture, test, and distribute products. The “G” stands for “Good,” and the “x” is a placeholder for the specific practice — GMP (Good Manufacturing Practice), GLP (Good Laboratory Practice), GCP (Good Clinical Practice), and so on.
A GxP system is any software, process, or infrastructure that directly supports or impacts activities governed by these regulations. That includes electronic quality management systems (eQMS), laboratory information management systems (LIMS), manufacturing execution systems (MES), and validation management platforms.
If a system touches GxP-regulated processes — documenting batch records, managing deviations, executing validation protocols — it falls within the GxP system definition. The regulatory expectation is clear: those systems must be fit for purpose and, where applicable, validated.
What are GxP compliance requirements?
GxP compliance requirements vary by region and specific practice area, but several foundational expectations apply across the board.
Data integrity sits at the core of every GxP framework. Regulatory agencies including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) consistently cite data integrity failures as a leading cause of enforcement action. The ALCOA++ principles — attributable, legible, contemporaneous, original, accurate, plus complete, consistent, enduring, and available — define the standard that GxP records must meet.
Audit trails are a non-negotiable feature of any GxP-compliant software. Systems must capture who did what, when, and why. For electronic systems specifically, 21 CFR Part 11 (in the US) and Annex 11 (in the EU) set out detailed requirements for electronic records and signatures, including audit trail depth, access controls, and system security.
Change control is another pillar. Any modification to a validated system — configuration changes, software updates, new integrations — must go through a documented change control process. Without it, the validated state of the system cannot be assured.
Traceability ties these requirements together. Regulators expect organizations to demonstrate a clear, documented link from user requirements through to testing evidence. That traceability is the backbone of a defensible validation.
GxP regulations: the regulatory landscape
GxP regulations are not a single document. They span multiple jurisdictions, agencies, and guidance bodies — and they continue to evolve.
In the US, the FDA’s 21 CFR Part 11 governs electronic records and signatures. Broader GMP requirements for pharmaceutical manufacturing fall under 21 CFR Parts 210 and 211. For medical devices, 21 CFR Part 820 applies.
In the EU, EU GMP Annex 11 covers computerized systems, while Chapter 4 governs documentation practices. The European Commission’s revised GMP framework is increasingly aligned with international standards, but key differences remain.
Globally, the International Society for Pharmaceutical Engineering (ISPE) GAMP 5 guidelines provide the industry’s most widely adopted framework for validating computerized systems. The recent GAMP AI Guide signals that artificial intelligence (AI) tools used in regulated environments are now firmly in scope for validation.
The FDA’s Computer Software Assurance (CSA) guidance, finalized in recent years, represents a significant shift in regulatory thinking — moving away from prescriptive, documentation-heavy validation toward a risk-based, assurance-focused model. CSA encourages organizations to concentrate effort where it matters most and reduce low-value documentation.
Why GxP compliance software needs to be validated
Choosing software that claims to be “GxP compliant” is not enough. Compliance is not a feature a vendor can fully deliver — it is a state an organization must demonstrate, for each specific use of a system, in their specific environment.
This is where validation becomes critical. Software validation is the process of establishing documented evidence that a system consistently does what it is intended to do, and that it meets the requirements of the users and the applicable regulations.
Validation typically follows a structured lifecycle: user requirements specification (URS), risk assessment, installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ). The depth of testing and documentation scales with the risk the system poses to product quality and patient safety — a principle reinforced by both GAMP 5 and the FDA’s CSA guidance.
Skipping or shortcutting validation creates real regulatory risk. During an inspection, an investigator will look for evidence that your GxP systems have been validated. Gaps in that evidence — missing test records, undocumented changes, unreviewed deviations — can result in observations, warning letters, or worse.
Choosing GxP compliance software: What validation teams should look for
With the pharmaceutical manufacturing software market expanding rapidly, validation professionals face a growing field of vendors making compliance claims. Here are the key factors that matter.
Vendor qualification support. A reputable GxP software vendor will provide a vendor audit pack, documentation of their software development lifecycle (SDLC), and evidence of how their development practices align with GAMP 5 or equivalent standards. This documentation directly supports your qualification activities.
Configurable vs. custom. GAMP 5 categorizes software by type, and the validation approach differs accordingly. Commercial off-the-shelf (COTS) software configured for your environment carries a different risk profile than bespoke custom software. Understanding where your solution sits on that spectrum shapes how you scope validation.
Audit trail and data integrity by design. Look for systems that make ALCOA++ compliance structural — not optional. Audit trails that can be turned off, or data fields that allow overwriting without a record, are red flags for any GxP environment.
Change management and release practices. How does the vendor manage software updates? Are release notes clear? Are you notified in advance of changes that could affect validated functionality? A vendor’s change management practices will directly affect your ongoing validation maintenance burden.
Support for your validation process. Some vendors go further than documentation. Purpose-built validation management platforms can accelerate IQ/OQ/PQ execution, centralize evidence, and provide the traceability regulators expect — all within a compliant, auditable environment.
The bottom line
The growth of the pharmaceutical manufacturing software market reflects real momentum toward digital transformation in the life sciences industry. But investment in new software only delivers value if that software is properly implemented, validated, and maintained in a state of compliance.
GxP compliance is not a one-time checkbox. It is an ongoing commitment — to data integrity, to documented change control, and to the validation practices that regulators expect. The right GxP compliance software, validated rigorously and maintained carefully, is a competitive asset. Done poorly, it is a liability.
